Drug Profile
AKS 107
Alternative Names: AKS-107Latest Information Update: 22 Mar 2024
Price :
$50
*
At a glance
- Originator Akston Biosciences
- Class Antihyperglycaemics; Insulins
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Type 1 diabetes mellitus
Most Recent Events
- 22 Mar 2024 AKS 107 is still in preclinical development for Type-1 diabetes mellitus in USA (Akston Biosciences Pipeline, March 2024)
- 11 Mar 2024 Pharmacodynamics and pharmacokinetics data from a preclinical study in Type-1 diabetes mellitus released by Akston Biosciences
- 28 Sep 2021 No recent reports of development identified for preclinical development in Type-1 diabetes mellitus(Prevention) in USA (SC, Injection)